We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

PBI Names Sheri' DuMond as its New Director of Business Development

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Pacific Biomarkers, Inc. has promoted Sheri' DuMond to Director of Business Development following her role as Senior Associate Director of Business Development at PBI.

In her new position, Ms. DuMond will oversee the Business Development Team and lead PBI's sales and marketing efforts to secure consistent revenue growth and optimize shareholder value. The Business Development Team is charged with promoting PBI's capabilities among target customers and to leverage opportunities that represent accumulative financial strength and stability for all functions within the Company.

Prior to joining PBI, Sheri's professional experience was rooted in the commercial side of the pharmaceutical industry, including positions at Novartis and Wyeth totaling 14 years. Sheri"s career path consistently led to positions of increasing responsibility in pharmaceutical sales; from a primary care sales representative, managed care/account manager, district sales manager, to national leadership team. Sheri' received her Bachelor of Science degree in mass communications/journalism/public relations from Seattle University.

Ron Helm, PBI's Chairman and Chief Executive Officer, said, "We are delighted to have Sheri' in the important role of Director of Business Development. The skills and ingenuity that she demonstrated while serving as our Senior Associate Director of Business Development make her eminently suited for the job, and we look forward to benefiting from her talents as we seek to grow our revenue in 2011 and beyond."